Harlan Levy was an attorney at the Federal Communications Commission's Cable Television Bureau before becoming a reporter at WGTR-AM in the Boston area. He then worked as a TV news reporter at WXEX-TV Richmond, VA., WCIX-TV Miami, FL (winning an Emmy), and WVIT-TV, West Hartford, CT. He was co-owner Levy-Horsfield Video Productions from 1990-1993. He was a reporter and Managing Editor for The Commercial Record (banking & real estate weekly newspaper, S. Windsor, CT) from 1993-1997, and a business reporter and columnist for the Journal Inquirer from 1997-present. Levy has several awards from the Connecticut Society of Professional Journalists, including first place for business stories in 2008. Levy is also a freelance reporter, with business stories appearing in The New York Times, starting in 2001.
He has an A.B. from Princeton University and a J.D. from New York University School of Law, and he is a member of the Connecticut Bar and the Washington D.C. Bar.
Professional investor and overall good guy.
By reading Mako Research reports, you agree to use the information at your own risk. In no event should Mako Research or any affiliated party be liable for any direct or indirect trading losses caused by information contained in the research reports. Research reports are not investment advice or a recommendation or solicitation to transact any securities. Mako Research is not a registered investment advisor. You agree to do your own research and due diligence before making any investment decision with respect to securities covered herein. You should assume that Mako Research stands to profit in the event the issuer’s stock declines. Research reports may contain opinions, which are based upon generally available public information, field research, inferences and deductions through due diligence and analytical processes. All information is believed to be accurate and reliable, and has been obtained from public sources. Mako Research makes no representation, express or implied, as to the accuracy, timeliness, or completeness of any such information. All expressions of opinion are subject to change without notice, and Mako Research is not obligated to update or supplement any reports or any of the information, analysis and opinion contained in them. You should assume that Mako Research has and/or will submit findings with the Securities Exchange Commission, and other entities that may find the information useful.
Nick Cox is a long-time entrepreneur and investor,currently living in Singapore.
His investment strategies are mostly based on Western companies but with particular understanding for economic currents in Asia,the leading driver of worldwide economic growth today and for the medium term.
We look for potentially undervalued stocks in biotech, technology, and commodities sectors.
We perform research, and give investment opinions and ideas to buy-side firms from time to time.
We do not discuss unpublished reports, or provide any advanced warning of future reports to others.
We are not advisors.
Business graduate from a working man's school after several years of stop and start and working full time and raising two families. Began playing with options in 2006, not very timely unless you can short with big bankroll, and have been doing so since, with more of an investment perpective while running my wife's rollover the last several months. Like mostly dividend paying, L/T record of growth, with a little spec including first mover/ biotech break through type companies that have a tremendous long term possibilities.
I'm an individual investor, I read up on companies before I decide to invest, I make my own decisions so that I can only blame myself for any mistakes I may make! I do find it strange when people on these advice sites run down companies that they have no investment in, and rarely give a positive as well as negatives. It makes me wonder if they have an ulterior motive for running down companies that they say they have no interests in! I think when an investor with a following has a bad beat, they look for excuses as to why this happened, when instead, they should take it on the chin admit they got it wrong and move on! These investments can go down as well as up! That's what I read everywhere! That's the only thing that is true!
I graduated from Boston University in 1981 with a BA in Finance. From 1983-1997, I was a spot currency trader on the desks of several European banks in NYC. Since 1997, I have been trading from home. I consider myself to be a student of markets, and market history. I believe so much can be learned from history, and examining the facts. I try never to make an assertion about economics or markets, without it being fact-based and not simply an opinion.
Investor since a decade, who invests cent percent of investment capital into equities and does his own research to chose long term winners, who will also be a decent bet for the medium term.
I manage the following, where you can follow me and interact at (free forever):
i. A Facebook page which conveys relevant business news, market information, views and insights ( facebook.com/WallStreetGuru )
ii. A Twitter handle where I share my picks, offer 'blatant' view on market events and answer questions: @ABraveBull
iii. A blog that I write on significant market events (http://www.sunnygoklani.com/brave-bull-updates).
I believe knowledge is cumulative and everyone has a unique contribution to make. We all collectively make this world a better place to co-exist.
Learning as I go. My investing experience is limited, but I believe that biotechnology/pharmaceuticals hold the key to the best returns in the next 5-10 years. Targeted therapy, monoclonal antibodies, and genetic treatment tailoring are the future of medicine.
I am a practicing Army Physician (Diagnostic Radiologist). My professional interests include neuroradiology, brain tumors, head and neck cancer, functional MRI, and emerging tagged imaging agents. I intend to apply for a fellowship in neuroradiology this coming Summer. As such, I intend my writing to be speculative, but directed by science and my experiences thus far in medicine with an optimistic essence.
CPA, Arthur Andersen
financial analyst, Equity Research, financial sector, Salomon Brothers
Institutional Equity Research Sales, Goldman Sachs
Private Wealth Manager, Goldman Sachs, Deutsche Bank, Credit Suisse and JP Morgan
MBA, Columbia Business School, Finance
BS, Univ of MD, College Park, MD, Accounting
Dallas currently owns and operates as CEO an Austin-based enterprise consulting firm that specializes in private company lifecycle management, up to and including taking companies public, and in helping consult publicly traded companies ranging in market cap from $100 million to $500 million. He has a specialization in deal flow management and is often the referring and closing source of Joint Ventures and broader M&A. Dallas often works directly with management teams and Boards of microcap and stressed equity companies in which he or members of his professional network are heavily invested. This includes helping with overall strategy, helping with capital structure management, helping facilitate liquidity, helping facilitate Joint Ventures and broader M&A, and helping restructure the business segments if necessary. Recently Dallas has been interviewed by The Pittsburgh Business Times, The Banker, Columbus Business First, Houston Business Journal, The Deal, Energy Intelligence, and his tweets have been used by CNBC to highlight hot button issues regarding Carl Icahn, Bill Ackman, Nelson Peltz’s takeover attempts at DuPont, etc. Dallas has also been quoted and sourced to by StreetSweeper.org, Marcellus.com, MarcellusDrilling.com, Bakken.com, OilOnline.com, and other physical and online publications. "One place of great inefficiency is in the stressed equity markets – or the markets in which a company appears as bankruptcy or a breakup is inevitable. As equities become stressed they often sell down to absurd levels of value that present, should there be value to be unlocked, opportunities for “venture level” returns. These often range in the 3X-10X range. With my unique ability to actually improve business outcomes by working directly with a company and management/Board I’m in a position, should I view the underlying business as salvageable, to directly improve the long-term viability of the company. I am NOT simply an investor in these names but an acting consultant. This allows me to “overlay my network” and to move the company away from a stressed or defaulting outcome and into an outcome probability that allows the equity price to move substantially higher. Identifying these opportunities has generated shareholders and investors thousands of percentage points in aggregate and is something I’m often recognized by paying subscribers for."
MD, MBA (Finance, NYU-Stern), certificate in financial modeling (Wharton). *Tipranks profile not accurate as doesn't pick up my premium ratings. Founder: Vasuda Healthcare Analytics (premium U.S. Biotech/pharma research) and Trident Asian Research (premium Asian investments research, www.tridentasia.com)
- Investment insights contributor: SumZero, Buy-side Institutional Platform (sumzero.com). Members of the platform include some of the largest hedge funds and asset managers.
-Former Insight Provider for Smartkarma Intelligent Investing (www.smartkarma.com): Institutional Investments Research Platform (was ranked among top 10 out of over 100 contributors). Clients included some of the largest hedge funds and asset managers.
- Buy-side equity research analyst covering mainly small-cap, emerging pharma/ biotech companies. M.D. with over 18 years of clinical experience (in the U.S. and India), still retaining full medical license in India. M.B.A. with finance and financial markets specialization from New York University Stern School of Business.
- Expert in picking healthcare-related investments, especially biotechnology and pharmaceuticals (focus on small, emerging companies). Investments are selected based on detailed due diligence, including proprietary DCF valuation models. Value investor with long-term horizon.
- Founder, managing principal of Vasuda Capital Management, healthcare-focused investment management firm, vasudacapitalmanagement.com. Registered Investment Advisor in Massachusetts.
- Also started and continue to sponsor Vasuda Global Orphan/ Rare disease biotechnology index, the first global equity index covering rare/orphan disease sector. Index quotes are available on bloomberg/reuters terminals.
Chris DeMuth Jr. is the founder of Rangeley Capital LLC. Rangeley is an investment firm that focuses on event driven, value-oriented investment opportunities. Rangeley Capital and his value investing forum, Sifting the World (StW), search the world for misplaced bets. Rangeley exploits them for its investors and then Mr. DeMuth writes about them on StW.
Investor and trader that has been involved with trading equities for several years. Former business owner/investor that bought failing companies and turned them around and into profitable companies. Specialize in finding up and coming and possible turn around companies.